Studies reported the SH2 domains of PTPN11 could bind to programmed cell death 1 (PD-1), an immune checkpoint target for cancer immunotherapy, to suppress T cell function and stimulate the immune escape of cancer cells [37, 38]. This evidence concerns the gene PDCD1 and cancer.